# Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

> **NCT00095862** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wiseman Research Initiatives LLC** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** allogeneic GM-CSF-secreting breast cancer vaccine
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00095862
- **Lead sponsor:** Wiseman Research Initiatives LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095862, "Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00095862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*